FDA Approves Ingrezza Sprinkle (valbenazine) for Tardive Dyskinesia and Chorea Associated with Huntington’s Disease.
FDA approves a new sprinkle version of Ingrezza for two movement disorders.
The FDA has approved Ingrezza Sprinkle, a VMAT2 inhibitor, for the treatment of adults with tardive dyskinesia and chorea associated with Hu…
FDA approves sprinkle form of Ingrezza to treat involuntary movements in adults with tardive dyskinesia or Huntington's disease chorea.
Luteolin shows neuroprotective potential in preclinical models for Alzheimer's, Parkinson's, Huntington's, and multiple sclerosis.
Luteolin shows potential benefits in early studies for neurodegenerative diseases
This review of preclinical studies and preliminary clinical observations suggests luteolin may reduce neuroinflammation and improve function…
Luteolin may help slow brain decline in Alzheimer's and Parkinson's by calming inflammation and boosting antioxidant defenses in early studi…
Ketamine shows cognitive effects in animal models but cognitive worsening in human Huntington's disease study
Can ketamine help brain injuries? Animal studies say maybe, but human evidence is thin.
A systematic review and meta-analysis of 22 studies (21 animal, 1 human) found ketamine showed positive cognitive effects in 93.2% of animal…
Animal studies suggest ketamine might help brain injuries, but the only human trial found it worsened thinking in patients with Huntington's…